Biocon Biologics has been positioning itself to become a global player in biosimilar drugs. Viatris, a longtime partner to Biocon, is charting a course for its future that does not include biosimilars ...

The Bengaluru-based drugmaker has approvals for biosimilar versions of Insulin Glargine, Insulin Aspart and Human Insulin.

The biosimilar fracas targeting AbbVie’s megablockbuster Humira is taking shape. But to Biocon Biologics CEO Shreehas Tambe, the battle doesn’t solely revolve around market share. Humira, also known ...

Feb 16 (Reuters) - Biocon is aiming for high-double-digit percentage revenue growth as the Indian pharmaceutical firm prepares to launch generic versions of weight-loss drugs globally ‌even as it ...

Biocon has named Peter Bains its next CEO as the company looks to expand its presence in North America and beyond. As part of the move, which became effective Monday, Bains will step down from ...

BENGALURU, Dec 6 (Reuters) - Indian biopharmaceutical company Biocon said on Saturday it would fully integrate its biosimilar unit Biocon Biologics as a wholly owned subsidiary, consolidating Biocon’s ...

Biocon Biologics is among the leading global suppliers of biosimilar insulins and has been expanding its portfolio ...

Stock market today: The Indian stock market remained under bearish pressure as the benchmark Sensex plunged another 800 ...

Biocon will fully integrate its biosimilars arm, Biocon Biologics into the parent, in a deal valuing the unit at $5.5 billion. The move is aimed at creating a unified biopharma powerhouse, and to ...

Viatris Inc. , the company formed by the merger of Mylan and Pfizer Inc. unit Upjohn in 2020, said Monday it has reached an agreement to combine its biosimilars portfolio with Biocon Biologics Ltd.

Biocon share price jumped over 4% to a fresh 52-week high on Thursday after reports stated that the company was evaluating an internal merger of its biosimilars arm, Biocon Biologics, with the parent ...

BENGALURU, Sept 17 (Reuters) - Biocon Ltd (BION.NS), opens new tab said late on Thursday its biologics unit will sell a 15% stake to a Serum Institute of India (SII) subsidiary for access to 100 ...